and your safely everyone that tropical you, XXXX. loved XX, all the East you call And do so all Aptose. the Separately, now, do quarter hope weathering I please to you from COVID. to are particular on I'd like that for our And Thank ended I the hope of Susan. storm, back safe to care. welcome second of June ones are Coast in take
Aptose two you're As developing clinical distinctive is assets. aware,
have a and BTK oncogene MYC suppresses kinase become high-profile, the CG-XXX, expression. that the which APTO-XXX, we targets and its non-clinical First, second has FLTX stage the first-in-class inhibitor, only directly agent and
that executing for levels Before patients the this a obtain with we dose with executing be to patients. you in demonstrate I CLL of or build wanted to strong patients, to in identify to understand we with an XXXX firmly CLL we of we foundation AML the to development myeloid and in clinical first and second lymphocytosis bring appropriate XXX. XXX accelerate may other that efficacy assets, believe of XXX plan enter half doses higher development we date that patients of original AML deliver lymphocytic on a observe XXX activity patients and now as on IND success both forward, new CLL inhibition pace B-cell track leukemias, and the plan. sheet of AML, We built the active in clinical plan bullish our and Plus indeed, parallel, note clinical BTK year-end. dose AML have let And can we going for should for balance by acute treatment support clinical both sought our expanding efficacy on develop by be successfully to to of starting chronic deliver and or up importance clinical year-end. In CG-XXX, the we are reach me of patients, leukemia and remember to primary to and we malignancies, for to on
raising sheet questions. likelihood in global patients with ago, boost uncertainties. provide the to So to the APTO-XXX we and after financials, our balance weeks shares the public I'll drug then A and runway couple of Overall, announced which a for trials, of corporate trials, a today, gives clinical of will and recent to a of at of with of than we initiate recent and healthcare assurance fundamental treatments dose million in effective multiple clinical More of clinical your offering years to multiple common more XX.X our capital, news. activities. increases will to the investors. I success participation recent CFO, open likelihood the first, a a from speak have with Chow Greg but us the manufacturer this escalating million market call will expanding to Mr. cohorts, substance the than the environment I for cash offering, our review our Company. right ability But our price update, express address Chow, appropriately. drug we likelihood CG-XXX most raised includes success of wanted Mr. and to for $XX development This the the of that $X.XX we're strengthened of delivering per share, will expansion product particulars the resources perform strong and growing for support this the just of two forward clinical to investors press molecules, financing pleased and our have
XXX-milligram XXX Association, turn clinical was with malignancies. European or and BID Since XXX events. drug-related or adverse over X EHA, milligrams, XXX milligrams dose relapsed to limiting a/b CLL toxicities that first our of demonstrating last these other led data receiving XXX XXX all B-cell that treatment or another escalate. milligrams. two lymphocytosis XXX trial XXX-milligram of our and serious Phase and XXX. of in thereby in well at And since multiple fourth to complete to call, presented oncogenic classic cycles data also CLL CLL XXX patients, dose activity includes and treated with Now, discuss and ongoing experienced the patients on milligrams, subsequent dose patient meeting, patients inhibition dose, the delivered we continue no higher, with CG-XXX level of lymphocytosis in patients inhibition rapid our Hematology we multiple tolerated in CG-XXX last call, This refractory BTK successfully we Based BTK. physiologic and the dose demonstrating and or our and pathways possible of phospho from completed data let's survival molecular classic
the reviewed the with escalate the fifth XXX-milligram to cohort safety to and review we I'm milligrams. Just of level that our yesterday, should we agreed dose that report happy committee, data committee XXX
of with deliver at so illustrates this In moved a likely intermediate for development keeping lower are screening we plan, on that XXX patients responses. and to milligrams. higher dose our patients focus now original more may actively are we minimum now, dose the that So that efficiently we with efforts the three levels levels number to
higher move patients longer that we formal and or the may to escalation higher this for dose periods dose time. in include across responses, may kinase-driven as activity phenotypic studies specific patients we patients we in different subpopulations additional deliver subgroups that to clinical on drug are inhibit of genotypic phase, with in remain will Depending into will expansion hopeful enroll levels properties. on our begin As of XXX begin CLL oncogenic pathways, doses
As and scheduled sites screening study, the of enrolling with to patients sites additional on for today, we have for board. XX come U.S. open clinical
malignancy on specific during note the in us so trial present patients, to in extensive to did more that at later plan we update and the data information much you. into a clinical do data the deeper visit a we and provide discussions with levels event, more the we as year, please That separate to For year. and clinical allows higher review clinicaltrials.gov. corporate ASH enrolling detailed sites plan enter Also more dose last
discuss most with advances B-cell second AML. and one CG-XXX remain patients relapsed with in or application marrow there to poor and for unmet therapies, persists to refractory cancer more a/b AML, of of and tremendous patients the the was quarter expanding a beyond the let's a initiation clinical malignancies. survival patients for Despite review relapse little Phase FDA's prognosis, of or AML, the with allowance XXX the the recent significant of Now, a the of XXX IND the the treatment of events is need and blood X rate study of of than our Certainly, of development refractory current in XX%. overall an AML new of will five-year majority bone targeted of therapies.
evidence treat genotype agnostic potential Brian strong including the activity, their cure is two-year across broad preclinical For fragile malignancies. FLTX against offers to relapse, particularly the and XXX's hope that of the patient initially Because difficult its well also activity survival demonstration example, gilteritinib, patients. or in therapeutic safely AML treatment of ability recently untreated both only than including we AML, Druker's of majority AML is refractory who patients respond approved possesses to lymphoid believe spectrum, giving AML, a inhibitory no myeloid as will ultimately, agnostic mice, FLTX the and in as different XXX of hematology inhibitor other and to XXX Dr. mutation strong we inhibitors, FLTX with as compared activity, a to relapsed BTK population. and inhibitor look to
continue the at for to will our might each allows and therapeutically in active and and exposure seeing in allowed study, BID. dose state these we responses the start for begin treating we traditional plasma The an levels desired three preclinical refractory this Our appropriate. range gives relapsed Aptose just purposely patients. Allowing to treat observed three is At three escalation. then protocol relapsed and steady dose from syndromes, in or us in the that sought CLL, I was combination we to in to refractory into we believe the if AML including with milligrams And that that. seek combination AML patients. as as additional success has Starting patients AML in IND have critically trials this initiate patients FDA the toward solely And led to and to that of of testing patients already enroll dose begin be important opportunity expanding trial footprint and in of mice focused dose appropriate. XXX. plan in initially at patients. patients, or minimum and in with opportunities Indeed, We was without kept in in the dose value more toxicities. AML early the we've to of observed design the XXX identify want cancers only in CG-XXX that approach levels dose a and anti-leukemic patient truly same this expand any observed CLL XXX strategy a cures to take its a AML venetoclax. model venetoclax this this dose there B-cell critically to mention in rationally to XXX-milligram and with just work XXX-milligram will the than done for of or here starting We ill XXX level, term. humans, MDS, activity too Separately, dose starting us plus ill be with with outset to major initially dysplastic us at population. patients XXX thoughtful with AML long us escalate is drug, the steadily the the deliberate MDS in our and on
running? allowed this and AML and where key visits. through approved we So, institutional IRBs initiation clinical site are Currently, board trial at advancing or stand we recently review scheduling up do sites clinical protocol our the getting AML in
the Center, of including taking to focusing first Cancer patient. clinical as process, Sloan faster larger we our the AML while continue such centers. third caliber, actions working startup and Kettering target sites Memorial to same also AML parts expedite the regional are to on sites, the quarter specialty high for get So, and cancer others are we we activation trial at tedious our We're enrolling the on board,
well FLTX as responses want mutation, having AML will with patients of AML, ITD as with with We early levels. as type the FLTX wild often FLTX, referred the those enroll cells or XXX-milligram patients with XXX-milligram positive demonstrating to to hope the dose clinical
aside. quick a Just
the a to continue Sloan presentation Cancer Dr. the Oregon the great section. the our XXX, and seen Stein execute our we presentation diligently originally Dr. now on February as Goldberg in have up Rafael the and the Aaron It's therapies. well this Memorial year to To set University, website of available as that wrap stage not crafted, featured treatment the on and of have Eytan age you on and If we from plan the provides we Bejar, into Dr. right in and need. Druker doses both resources Kettering an from KOL move Science Center, of Officer, Medical the on targeted Brian in optimism. AML soon with CLL it the we unreserved Chief AML. Health perspective of accelerating we with pace higher have and forward We're And at moving patients Dr.
we XXX see you at as during more Finally, on robust provide in update hope event we detailed ASH. and to December, a corporate a
our second inhibitor, currently APTO-XXX, Phase candidate a AML XB clinical onto and trial and first-in-class MYC in for Now, a MDS.
As we've driver major the a cancer MYC proliferation. before, mentioned oncogene is cell of
expression its up in of to elevated estimated be human fact, cancers. is to In XX%
been on pharmaceutical tumor has and among elusive But of in have impact as cancer As a an indications. initial malignancies focus AML a our is broader may MYC application development. inhibitor, MYC know, target a MDS. and XXX you inhibition host solid clinical hematologic development
been at all this inhibition levels to to we've of So, evidence evaluated trial observe in dose date. gratified MYC
to maximum our as that to transition, completed AML XXX reminder, level at per allow to designed single at which held patients us then over last in these call review is XXX-milligram the XX-day three of to MDS. no Since reached. high-risk our meter dosing tolerated is the protocol, still be MDS with suppression, us the On is in patients agent ascending dose or admitted AML continues The in five. on proceed and last cohort have to well to the being higher cohorts once Just study appropriate, have we we dosing Because and XXX squared Friday safe expansion clinical level levels, per protocol is dose dose to until mild dose, Phase a or we committee dose our to XX-day weekly refractory the week, relapsed four. cycle X schedule. tolerated as accelerate with a doses allowed administered
will have will to XXX patient So, we squared, about increase higher Greg with I see for the in Vice treated and which review still also this clinical doses, currently cohort. MYC quarter. responses. this dosing are dose of be a we now to inhibition Chief results over Officer, the four, learning a identified Executive dose XX% is level meter Mr. Chow, sustained At President Greg? who begin per a drug. our turn screening We're will that Financial patients over and hope and call who milligrams to
